PHILADELPHIA, Jan. 27, 2026 /PRNewswire/ -- Investor protection firm Kaskela Law LLC is investigating the proposed buyout of FONAR Corp. (NASDAQ: FONR) ("FONAR") to determine whether the proposed buyout price materially undervalues the company's shares and shortchanges the company's investors. Click here for additional information: https://kaskelalaw.com/case/fonar-corp/ On December 29, 2025, FONAR announced that it had agreed to be acquired at a price of $19.00 per share in cash. Following the closing of t ...

NEW YORK, Jan. 21, 2026 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who hold stock of FONAR Corporation ("FONR" or the "Company") (NASDAQ: FONR). You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into potential breaches of fiduciary duty by the officers and directors of FONAR Corporation.  To learn more about the action and your rights, go to: https://zlk.com/mna2/fonar-corporation-lawsuit-submission-form or ...

Merger Investigations - RAPT Therapeutics will be acquired by GlaxoSmithKline LLC for $58.00 per share, with an estimated aggregate equity value of $2.2 billion. The investigation focuses on whether the RAPT Board breached its fiduciary duties by failing to conduct a fair process and whether the deal provides fair value to shareholders [2] - Calavo Growers will be acquired by Mission Produce, Inc. for $27.00 per share, consisting of $14.85 in cash and 0.9790 shares of Mission for each share of Calavo, valuing Calavo at approximately $430 million. The investigation concerns potential breaches of fiduciary duties by the Calavo Board regarding the fairness of the deal [4] - Penumbra will be acquired by Boston Scientific Corporation in a cash and stock transaction valuing Penumbra at $374 per share, with an enterprise value of approximately $14.5 billion. The investigation examines whether the Penumbra Board failed to conduct a fair process and whether the deal consideration is fair [6] - FONAR Corporation will be acquired by FONAR, LLC and FONAR Acquisition Sub, Inc. for $19.00 per share in an all-cash transaction. The investigation looks into whether the FONAR Board breached its fiduciary duties by not ensuring a fair process and fair value for shareholders [8]

Group 1 - The last commentary on FONAR Corporation (FONR) was in September of the previous year, resulting in a downgrade of the company due to shares trading at $15.60, which subsequently fell below $14 [1] - The company specializes in magnetic resonance imaging (MRI) technology [1] Group 2 - The commentary reflects a strategy focused on investing in undervalued profitable stocks with strong balance sheets and minimal debt [1] - The approach includes writing calls against positions to generate additional income and managing risk through position sizing and trailing stop losses [1]

Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask: About Monteverde & Associates PC NEW YORK, Jan. 5, 2026 /PRNewswire/ --Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Clas ...

FDA Approvals & Rejections - ARS Pharma's neffy, a needle-free epinephrine nasal spray for emergency treatment of Type I allergic reactions, received approval in China, with commercial availability expected in spring 2026. The product generated $31.3 million in U.S. revenue in Q3 2025 [3][4]. - Vanda Pharmaceuticals' NEREUS, an oral NK-1 receptor antagonist for preventing motion-induced vomiting, received FDA approval, marking the first new treatment for motion sickness in over 40 years. The drug demonstrated a meaningful reduction in vomiting in clinical trials [5][6]. Clinical Trials - Breakthroughs & Setbacks - InflaRx's analyses from a halted Phase 3 trial of Vilobelimab in pyoderma gangrenosum indicated potential efficacy signals with longer treatment duration, prompting plans to discuss alternative endpoints with the FDA [15][17]. - SELLAS reported that survival in its Phase 3 REGAL trial for Galinpepimut-S (GPS) in acute myeloid leukaemia is extending longer than anticipated, potentially increasing the likelihood of a positive outcome [18][19]. - Ultragenyx announced that its Phase 3 studies for Setrusumab in Osteogenesis Imperfecta failed to meet primary endpoints, leading to a decline in investor confidence [20][21]. - Genmab decided to discontinue clinical development of Acasunlimab to focus on higher-priority programs, with no impact expected on its full-year 2025 financial guidance [22][23]. Corporate Actions - FONAR Corporation agreed to be taken private by a CEO-led acquisition group for $19.00 per share, valuing the transaction at a significant premium. The deal is expected to close in Q3 2026, subject to shareholder approval [12][13][14].

Market Overview - The U.S. stock market is closing 2025 on a cautious note, with major index futures edging lower, extending a three-session losing streak, and hopes for a year-end "Santa Claus" rally fading [1] - Despite the recent pullback, 2025 has been a remarkable year for equities, with the S&P 500 poised for its third consecutive year of double-digit gains [1] Premarket Trading and Futures Movements - As of early Wednesday, U.S. stock futures indicated a softer open, with Nasdaq 100 futures down 0.43%, S&P 500 futures down 0.28%, and Dow Jones futures down 0.14% [2] - The S&P 500, Nasdaq Composite, and Dow Jones all finished slightly lower on Tuesday, marking the third consecutive day of losses [2] Commodities Market - Crude oil futures were trading lower by 0.38%, around $57.72 per barrel, while Gold Spot was down 0.35% to approximately $4,324.59 per ounce [3] Major Market Indexes Performance - The S&P 500 is on track for an annual gain of 17-18%, the Dow Jones has advanced 13-14%, and the Nasdaq Composite has jumped nearly 21% in 2025 [4] - This performance marks the S&P 500's third consecutive year of double-digit returns, a rare achievement since the 1940s [4] Federal Reserve Outlook - The Federal Reserve is expected to cut rates in 2026, with uncertainty regarding the extent and pace due to internal divisions and mixed economic data [6] - The FOMC approved a quarter-point reduction in December 2025, bringing the main interest rate to a range between 3.5% and 3.75% [6] - Inflation remains above the Fed's 2% target, with unemployment rising to 4.6% in November and only 64,000 jobs added [6] Corporate Developments - Vanda Pharmaceuticals shares surged over 18% after receiving FDA approval for its drug NEREUS [13] - Nike shares rose 1.54% following CEO Elliott Hill's purchase of approximately $1 million in company shares [13] - Nvidia's stock surged approximately 180% in 2025, driven by robust demand for AI chips, with ByteDance planning to increase spending on Nvidia's AI chips to around $14 billion in 2026 [13] - Urgent.ly Inc. shares rose significantly after the adjournment of its annual stockholder meeting [13] - Applied Digital announced a proposed merger with EKSO Bionics, leading to a 40% surge in EKSO shares [13] - FONAR Corporation shares surged 28.4% after confirming its acquisition by an insider-led group [13] - Society Pass Incorporated shares jumped 16.4% following a newly priced public offering [13] - Palantir and Tesla saw their shares decline amidst concerns about technology giants' capital expenditures [13] - Boeing shares advanced 0.6% after being awarded an $8.58 billion contract by the Defense Department [13] - Meta Platforms shares ended up 1.1% following its acquisition of an AI startup for over $2 billion [13]

Core Viewpoint - Ademi LLP is investigating FONAR for potential breaches of fiduciary duty and legal violations related to a recent transaction involving management and board members [1] Group 1: Transaction Details - FONAR stockholders will receive $19.00 per share for common stock, $6.34 per share for Class C common stock, and $10.50 per share for Class A non-voting preferred stock [3] - The transaction includes significant benefits for FONAR insiders as part of change of control arrangements [3] Group 2: Investigation Focus - The transaction agreement imposes a significant penalty on FONAR for accepting competing bids, which may limit shareholder options [4] - The investigation will assess whether the FONAR board is fulfilling its fiduciary duties to all shareholders [4]

Market Sentiment - The CNN Money Fear and Greed index showed a decline in overall market sentiment, remaining in the "Neutral" zone with a reading of 48.9, down from 49.1 [4] - U.S. stocks settled lower, with the Dow Jones index falling 0.2% and the S&P 500 recording losses for the third consecutive session [1][3] Economic Data - The Case-Shiller Home Price Index increased by 1.3% year-over-year in October, slightly lower than the previous month's 1.4% surge but above market estimates of 1.1% [2] - The FHFA house price index rose by 0.4% in October, rebounding from a 0.1% decline in September and exceeding market expectations of a 0.1% increase [2] - The Chicago Business Barometer surged to 43.5 in December from 36.3 in the previous month, surpassing market expectations of 39.5 [2] Sector Performance - Most sectors on the S&P 500 closed negatively, with consumer discretionary, industrials, and financials experiencing the largest losses [3] - Energy and communication services sectors closed higher, contrasting with the overall market trend [3]

Core Viewpoint - The proposed sale of FONAR Corporation to affiliates of CEO Timothy Damadian and certain executives and directors is under investigation to assess whether the offered consideration adequately reflects the company's value [1]. Summary by Relevant Sections - **Proposed Transaction Details** - Shareholders of FONAR will receive $19.00 per share for common stock, $19.00 per share for Class B common stock, and $6.34 per share for Class C common stock [1]. - **Investigation Purpose** - Kahn Swick & Foti, LLC is investigating the adequacy of the proposed sale consideration and the process leading to this valuation to determine if it undervalues the company [1].